This article spotlights interviews EMJ conducted with two leading specialists in multidisciplinary care of patients with cancer: Russell Petty, Ninewells Hospital and Medical School, University of Dundee and NHS Tayside, Scotland, UK, and Helmut Popper, Institute of Pathology, Medical University of Graz, Austria. The experts provide unique insights into topics such as the inclusion of molecular pathology, the feasibility of early testing, and the importance of informatics in the multidisciplinary team (MDT) approach.
Latest articlesAll articles
Infographic: ESMO Recommendations for Diagnosis and Staging of Metastatic Non-Small-Cell Lung Cancer
ESMO Recommendations for Diagnosis and Staging of Metastatic Non-Small-Cell Lung Cancer. Bronchoscopy: for central lesions; can be paired with bronchial washing, brushing, and bronchial and transbronchial biopsy
Novel Biomarkers and Drug Targets in Non-Small Cell Lung Cancer
Despite therapeutic advances, the prognosis of non-small cell lung cancers (NSCLC) is still very poor, especially when first diagnosed at later stages involving metastases. NSCLC classification can be aided by identifying genetic, molecular, and histological subtypes that are important biomarkers in treatment selection. The majority of targeted therapies are now first-line treatment options for eligible patients with advanced stages of NSCLC.
Neratinib as a Potential Therapeutic for Mutant RAS and Osimertinib-Resistant Tumours
Neratinib was developed as an irreversible catalytic inhibitor of ERBB2, which also acts to inhibit ERBB1 and ERBB4. Neratinib is U.S. Food and Drug Administration (FDA)-approved as a neo-adjuvant therapy for use in HER2+ breast cancer.
The Contradictory Phenomena: Development of a New Life and a Life-Threatening Illness: Colorectal Cancer in Pregnancy
Colorectal cancer (CRC) ranks as the third most common type of cancer in women. Patients aged 50 years and above constitute the highest percentage of patients diagnosed with the disease.